Article Text
Abstract
Introduction/Background Cervical cancer (CC) is caused by high-risk human papillomavirus (HPV), and for this reason immunity has a major role in its genesis. Regulatory T cells (Tregs) are a key element in the specific immune response with major activity as immunosuppressors.Tregs overexress transcription factor Forkhead/winged-helix P3 (FOXP3), which is considered a marker for their lineage fidelity. It is therefore expected that that high levels of infiltrating FOXP3+ Tregs in CC patients would be associated with more aggressive course and higher metastatic potential.
The aim of this study was to determine whether there is a relationship between the intratumoral and stromal infiltration by Foxp3+ Tregs and some pathological parameters in patients with CC.
Methodology This is a retrospective study of patients diagnosed between 2015 and -2020. All patients had histologically proven CC and they were examined for intertumoral and stromal Foxp3 expression by conventional immunohistochemistry.
Results 150 patients with the following pathological characteristics were included (table 1).
Intratumoral and stromal infiltration correlated linearly between each other (p<0.001) independently of tumor size, nodal involvement and age. Histological subtype differentially affected intratumoral and stromal infiltration. Squamous histology was associated with significantly lower stromal infiltration by FOXP3+ Tregs (p<0.001). On the other hand same histology was associated with higher intratumoral infiltration by FOXP3+ Tregs (p<0.001). More importantly there seems to be gradual increase in intratumoral infiltration from adenocarcinoma through adenosquamous to squamous histology.
Conclusion Infiltration by FOXP3+ Tregs in CC was not associated with tumor size and lymph node involvement, but showed very strong dependence on histological subtype. This observation suggests differential role of Tregs in immune surveillance and its escape across various histological subtypes, which may have direct implications to novel immunotherapeutic approaches in those patients.
Disclosures The authors have no relevant financial or non-financial interests to disclose.